AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
THIS AMEDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 15th day of April, 2020, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Charles Romp (“Executive”).
ContractCommercial Supply Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
THIS COMMERCIAL SUPPLY AGREEMENT (together with all Appendixes and Schedules attached hereto and all Purchase Orders (as defined in Appendix A) entered into by the Parties, the “Agreement”) is made on June 13, 2019 (the “Effective Date”) by and between Seattle Genetics, Inc., a Delaware corporation with an office at 21823 30th Drive S.E., Bothell, WA 98021 (“CUSTOMER”) and ESTEVE QUÍMICA, S.A., a corporation organized under the laws of Spain, with an office at Torre ESTEVE, Pg. Zona Franca, 109
AMENDMENT NO. 1 COMMERCIAL SUPPLY AGREEMENTSupply Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 (the “Amendment”) is effective as of April 14, 2020 (the “Amendment Effective Date”) by and between Seattle Genetics, Inc. (“Customer”) having a principal place of business at 21823 30th Drive SE, Bothell, WA 98021 and Esteve Quimica, S.A., (“EQ”) with an office at Torre ESTEVE, Pg. Zona Franca, 109 08038 Barcelona, SPAIN.
Amendment No. 1 to License AgreementLicense Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to License Agreement (this “Amendment”) is effective as of April 23, 2020 (“Amendment Effective Date”) by and between Cascadian Therapeutics, Inc., a Delaware corporation formerly known as Oncothyreon Inc. (“Oncothyreon”), and Array BioPharma, Inc., a Delaware corporation (“Array”).
Commercial Supply Agreement between Seattle Genetics, Inc. and Corden Plankstadt Dated as of February 20, 2020Commercial Supply Agreement • July 31st, 2020 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
This Commercial Supply Agreement (“Agreement”), dated as of February 20, 2020 (“Effective Date”), is hereby made by and between Seattle Genetics, Inc., a company organized and existing under the laws of the State of Delaware, USA (“Seattle Genetics”), and Corden Plankstadt, a company duly organized and existing under the laws of Germany (“Corden”).
